1
|
Bensaber H, Cacheux V. [Epcoritamab - relapsed or refractory large diffuse B cells lymphoma after two or more lines of systemic therapy]. Bull Cancer 2024:S0007-4551(24)00117-6. [PMID: 38631985 DOI: 10.1016/j.bulcan.2024.02.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2024] [Accepted: 02/16/2024] [Indexed: 04/19/2024]
Affiliation(s)
- Hedi Bensaber
- CHU d'Estaing, 1, rue Lucie-et-Raymond-Aubrac, 63100 Clermont-Ferrand, France.
| | - Victoria Cacheux
- CHU d'Estaing, 1, rue Lucie-et-Raymond-Aubrac, 63100 Clermont-Ferrand, France
| |
Collapse
|
2
|
Raynaud C, Rodrigues M. [Dostarlimab plus chemotherapy for primary advanced or recurrent endometrial cancer]. Bull Cancer 2024:S0007-4551(24)00075-4. [PMID: 38493028 DOI: 10.1016/j.bulcan.2024.01.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2024] [Accepted: 01/08/2024] [Indexed: 03/18/2024]
Affiliation(s)
- Charles Raynaud
- Département d'oncologie médicale, Institut Curie - Saint-Cloud, 35, rue Dailly, 92210 Saint-Cloud, France.
| | - Manuel Rodrigues
- Département d'oncologie médicale, Institut Curie, 26, rue d'Ulm, 75005 Paris, France; DRUM Team, Inserm U830, Institut Curie, 26, rue d'Ulm, 75005 Paris, France
| |
Collapse
|
3
|
Amokrane K, Cherel M, Rouzaire PO, Walencik A, Dubois V. [Relapse with HLA loss after hematopoietic stem cell transplantation with non-HLA identical donor: Guidelines from the Francophone society of bone marrow transplantation and cellular therapy (SFGM-TC)]. Bull Cancer 2024; 111:S14-S21. [PMID: 37061368 DOI: 10.1016/j.bulcan.2023.03.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2023] [Revised: 03/13/2023] [Accepted: 03/15/2023] [Indexed: 04/17/2023]
Abstract
Loss of heterozygosity or HLA loss is a genomic-type escape mechanism highlighted in certain types of relapses after allogeneic hematopoietic stem cell transplantation with a non-HLA identical donor, and especially after haplo-identical transplantation. The diagnosis must be made with certainty because the result conditions the therapy. In this article, the different mechanisms and techniques that can be used for the diagnosis of loss of heterozygosity, as well as the therapeutic options are reviewed, making it possible to establish clinico-biological recommendations for the diagnosis confirmation and management of the patients in relapse.
Collapse
Affiliation(s)
- Kahina Amokrane
- Gustave-Roussy, centre de lutte contre le cancer, 114, rue Édouard-Vaillant, 94805 Villejuif, France
| | | | - Paul-Olivier Rouzaire
- EA(UR)7453 CHELTER-université de Clermont Auvergne, service d'histocompatibilité et d'immunogénétique, CHU de Clermont-Ferrand, Clermont-Ferrand, France
| | - Alexandre Walencik
- EFS Centre-Pays de la Loire, laboratoire histocompatibilité, Nantes, France
| | - Valérie Dubois
- Laboratoire HLA, EFS Auvergne Rhône Alpes, Lyon, France.
| |
Collapse
|
4
|
Goncalves L, Tran VT, Chauffier J, Bourdin V, Nassarmadji K, Vanjak A, Bigot W, Burlacu R, Champion K, Lopes A, Depont A, Borrero BA, Mangin O, Adle-Biassette H, Bonnin P, Boutigny A, Bonnin S, Neumann L, Mouly S, Sène D, Comarmond C. [Clinical characteristics and follow-up of 60 patients with recent diagnosis of giant cell arteritis, NEWTON study]. Rev Med Interne 2024:S0248-8663(23)01322-X. [PMID: 38216390 DOI: 10.1016/j.revmed.2023.12.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2023] [Revised: 12/05/2023] [Accepted: 12/17/2023] [Indexed: 01/14/2024]
Abstract
INTRODUCTION The management of giant cell arteritis (GCA) has evolved with the arrival of tocilizumab (TCZ) and the use of PET/CT. Our objective is to describe the characteristics and followup of patients with recent diagnosis of GCA in current care. PATIENTS AND METHODS The NEWTON cohort is a monocentric retrospective cohort based on data collected from 60 GCA patients diagnosed between 2017 and 2022 according to the ACR/EULAR 2022 criteria. RESULTS The median age at diagnosis was 73 [68.75; 81] years old. At diagnosis, the main manifestations were unusual temporal headaches in 48 (80 %) and an inflammatory syndrome in 50 (83 %) patients. Temporal artery biopsy confirmed the diagnosis in 49/58 (84 %) patients. Doppler of the temporal arteries found a halo in 12/23 (52 %) patients. The PET/CT found hypermetabolism in 19/43 (44 %) patients. Prednisone was stopped in 17.5 [12.75; 24.25] months. During follow-up, 22 (37 %) patients received TCZ. At least one complication of corticosteroid therapy was observed in 22 (37 %) patients. After a median follow-up of 24 [12; 42] months, 25 (42 %) patients relapsed. At the end of the follow-up, 29 (48.3 %) patients were weaned from corticosteroid therapy and 15 (25 %) were on TCZ. CONCLUSION Despite the increasing use of TCZ in the therapeutic arsenal and of the PET/CT in the imaging tools of GCA patients, relapses and complications of corticosteroid therapy remain frequent, observed in more than a third of patients.
Collapse
Affiliation(s)
- L Goncalves
- Médecine interne, hôpital Lariboisière, université Paris Cité, Paris, France
| | - V-T Tran
- Centre d'épidémiologie clinique, hôpital Hôtel-Dieu, université Paris Cité, Paris, France
| | - J Chauffier
- Médecine interne, hôpital Lariboisière, université Paris Cité, Paris, France
| | - V Bourdin
- Médecine interne, hôpital Lariboisière, université Paris Cité, Paris, France
| | - K Nassarmadji
- Médecine interne, hôpital Lariboisière, université Paris Cité, Paris, France
| | - A Vanjak
- Médecine interne, hôpital Lariboisière, université Paris Cité, Paris, France
| | - W Bigot
- Médecine interne, hôpital Lariboisière, université Paris Cité, Paris, France
| | - R Burlacu
- Médecine interne, hôpital Lariboisière, université Paris Cité, Paris, France
| | - K Champion
- Médecine interne, hôpital Lariboisière, université Paris Cité, Paris, France
| | - A Lopes
- Médecine interne, hôpital Lariboisière, université Paris Cité, Paris, France
| | - A Depont
- Médecine interne, hôpital Lariboisière, université Paris Cité, Paris, France
| | - B A Borrero
- Médecine interne, hôpital Lariboisière, université Paris Cité, Paris, France
| | - O Mangin
- Médecine interne, hôpital Lariboisière, université Paris Cité, Paris, France
| | | | - P Bonnin
- Physiologie, hôpital Lariboisière, Paris, France
| | - A Boutigny
- Physiologie, hôpital Lariboisière, Paris, France
| | - S Bonnin
- Ophtalmologie, hôpital Lariboisière et Fondation Rothschild, Paris, France
| | - L Neumann
- Neurologie, hôpital Lariboisière, Paris, France
| | - S Mouly
- Médecine interne, hôpital Lariboisière, université Paris Cité, Paris, France
| | - D Sène
- Médecine interne, hôpital Lariboisière, université Paris Cité, Paris, France
| | - C Comarmond
- Médecine interne, hôpital Lariboisière, université Paris Cité, Paris, France.
| |
Collapse
|
5
|
Chanut M, Herbaux C. [Lisocabtagene maraleucel CAR-T cells - second line treatment in patients with relapsed or refractory large B cell lymphoma]. Bull Cancer 2023; 110:986-988. [PMID: 37661551 DOI: 10.1016/j.bulcan.2023.06.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2023] [Revised: 06/11/2023] [Accepted: 06/14/2023] [Indexed: 09/05/2023]
Affiliation(s)
- Mathilde Chanut
- Hôpital Saint-Louis, service d'hématologie-oncologie, 1, avenue Claude-Vellefaux, 75010 Paris, France.
| | - Charles Herbaux
- Hôpital Saint-Eloi, service d'hématologie clinique, 80, avenue Augustin-Fliche, 34090 Montpellier, France
| |
Collapse
|
6
|
Fileni C, Sarkozy C. [Pirtobrutinib in covalent BTK-inhibitor pre-treated relapsed/refractory (R/R) Mantle Cell Lymphoma]. Bull Cancer 2023; 110:988-990. [PMID: 37658026 DOI: 10.1016/j.bulcan.2023.07.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2023] [Accepted: 07/09/2023] [Indexed: 09/03/2023]
|
7
|
Montes L, Herbaux C. [Moxetumomab pasudotox-Third line in Hairy cell leukemia]. Bull Cancer 2021; 108:1073-1074. [PMID: 34776118 DOI: 10.1016/j.bulcan.2021.07.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2021] [Accepted: 07/14/2021] [Indexed: 10/19/2022]
Affiliation(s)
- Lydia Montes
- CHU d'Amiens, service hématologie et thérapie cellulaire, 80000 Amiens, France.
| | - Charles Herbaux
- CHU de Montpellier, service hématologie, 34295 Montpellier, France
| |
Collapse
|
8
|
Idrissi Samlali W, Ghailan T, Karjouh K, Ahami AOT, Azzaoui FZ. [Early maladaptive schemes and relapse during methadone maintenance treatment among drug addicts (a cognitive approach)]. Encephale 2021; 48:538-545. [PMID: 34756717 DOI: 10.1016/j.encep.2021.06.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2021] [Revised: 05/11/2021] [Accepted: 06/03/2021] [Indexed: 10/20/2022]
Abstract
INTRODUCTION/OBJECTIVE Dysfunction of cognitive schemas and addictive behaviors are often coexisting which can cause relapse during drug treatment. The objective of this study is to assess early maladaptive schemas (EMS) among heroin users and their relationship with relapse during methadone maintenance treatment. SUBJECT AND METHODS This is a cross-sectional study carried out on 166 heroin users treated with methadone at the medico-psychological center in northern Morocco during 2017. The subjects completed both the Young short version schema questionnaire (YQS) and the ASI questionnaire (Addiction Severity Index) to measure the severity of drug addiction. RESULTS The results showed that the most activated schemas in the totality of the subjects were fear of losing control, Emotional deficiency and failure. They were also significantly more activated in women than in men for five schemas indicating rejection and separation, and a lack of autonomy. Regarding the relapse during treatment consumption there was a positive and significant correlation with ten out of thirteen SPI, which means the more the intensity of SPI decrease the greater the tendency to relapse (r=0.509, P<0.0001). However, there was also a weak correlation between the consumption of other drugs and SPI. CONCLUSION The cognitive approach has highlighted the essential role of cognitive disorders in addictive behaviors that EMS may be predictors of relapse during substitution treatment, and that a concurrent therapy of schema may reduce the likelihood of relapse.
Collapse
Affiliation(s)
- W Idrissi Samlali
- Équipe neurosciences et nutrition appliquée, laboratoire nutrition, santé et environnement, département de biologie, faculté des sciences, université Ibn Tofail, BP. 133, Kenitra, Maroc.
| | - T Ghailan
- Unité de formation et recherche de pneumologie, centre des études doctorales SVS, université Mohammed V Suissi, 10170 Rabat, Maroc
| | - K Karjouh
- Équipe neurosciences et nutrition appliquée, laboratoire nutrition, santé et environnement, département de biologie, faculté des sciences, université Ibn Tofail, BP. 133, Kenitra, Maroc
| | - A O T Ahami
- Équipe neurosciences et nutrition appliquée, laboratoire nutrition, santé et environnement, département de biologie, faculté des sciences, université Ibn Tofail, BP. 133, Kenitra, Maroc
| | - F-Z Azzaoui
- Équipe neurosciences et nutrition appliquée, laboratoire nutrition, santé et environnement, département de biologie, faculté des sciences, université Ibn Tofail, BP. 133, Kenitra, Maroc
| |
Collapse
|
9
|
Mathian A, Pha M, Amoura Z. [Therapeutic de-escalation in systemic lupus erythematosus in remission]. Rev Med Interne 2020; 41:795-799. [PMID: 33234319 DOI: 10.1016/j.revmed.2020.11.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2020] [Accepted: 11/15/2020] [Indexed: 11/26/2022]
Affiliation(s)
- A Mathian
- Sorbonne université, Assistance Publique-Hôpitaux de Paris, groupement hospitalier Pitié-Salpêtrière, Centre de Référence pour le Lupus, le Syndrome des anti-phospholipides et autres maladies auto-immunes rares, service de médecine Interne 2, institut E3M, Inserm UMRS, centre d'immunologie et des maladies infectieuses (CIMI-Paris), Paris, France
| | - M Pha
- Sorbonne université, Assistance Publique-Hôpitaux de Paris, groupement hospitalier Pitié-Salpêtrière, Centre de Référence pour le Lupus, le Syndrome des anti-phospholipides et autres maladies auto-immunes rares, service de médecine Interne 2, institut E3M, Inserm UMRS, centre d'immunologie et des maladies infectieuses (CIMI-Paris), Paris, France
| | - Z Amoura
- Sorbonne université, Assistance Publique-Hôpitaux de Paris, groupement hospitalier Pitié-Salpêtrière, Centre de Référence pour le Lupus, le Syndrome des anti-phospholipides et autres maladies auto-immunes rares, service de médecine Interne 2, institut E3M, Inserm UMRS, centre d'immunologie et des maladies infectieuses (CIMI-Paris), Paris, France.
| |
Collapse
|
10
|
Alexandre J, Le Frere-Belda MA, Prulhiere K, Treilleux I, Leary A, Pomel C, Chargari C, Ducassou A, Joly F. [Nice-Saint-Paul de Vence 2020 recommendations for clinical practice: Management of metastatic and/or relapsing endometrial cancer]. Bull Cancer 2020; 107:1006-1018. [PMID: 32958220 DOI: 10.1016/j.bulcan.2020.06.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2020] [Accepted: 06/15/2020] [Indexed: 11/15/2022]
Abstract
Endometrial cancer is a common cancer in older women and is often associated with comorbidities. Management of metastatic disease and/or relapse requires a multidisciplinary approach. Recent advances in the understanding of oncogenesis and molecular classification of endometrial cancers offer new therapeutic perspectives. These first recommendations, established following the methodology of Nice-Saint-Paul recommendations for clinical practice (RPC), aims to integrate molecular advances in diagnostic and therapeutic management. In 2020, the histological diagnosis of endometrial cancer is based on morphology and immunohistochemistry, including at least p53, oestrogen and progesterone receptors. Deficiency in the DNA mismatch repair system (MMR) must be assessed in all advanced endometrial tumors for oncogenetic and theranostic purposes. It can be sought initially by an analysis in immunohistochemistry with the 4 markers (MLH1, MSH2, MSH6, PMS2). Medical treatment depends on histological type, presence of hormone receptors and patient's profile to refer to chemotherapy (carboplatin-paclitaxel) or hormone therapy (for example of the progestogen type); in the event of MMR-deficiency, immunotherapy trial is the best option. As part of overall management of advanced endometrial cancer, radiotherapy (and surgery in rare cases) must be discussed, in particular in the event of loco-regional only relapse or oligometastatic disease.
Collapse
Affiliation(s)
- Jérôme Alexandre
- AP-HP, centre université de Paris, site Cochin, service d'oncologie médicale, 123, boulevard de Port Royal, 75014 Paris, France.
| | - Marie Aude Le Frere-Belda
- AP-HP, centre université de Paris, site HEGP, service d'anatomie pathologie, 20-40, rue Leblanc, 75015 Paris, France
| | - Karine Prulhiere
- Polyclinique Courlancy, 38, rue De Courlancy, 51100 Reims, France
| | - Isabelle Treilleux
- Centre Léon Bérard, service d'anatomie pathologie, 28, rue Laennec, Lyon, France
| | - Alexandra Leary
- Institut Gustave-Roussy, département de médecine, 114, rue Édouard-Vaillant, 94800 Villejuif, France
| | - Christophe Pomel
- Université d'Auvergne, centre Jean-Perrin, service de chirurgie oncologique, UMR Inserm 1240, 58, rue Montalembert, BP 392, 63011 Clermont-Ferrand cedex 01, France
| | - Cyrus Chargari
- Institut Gustave-Roussy, département de radiothérapie, service de curiethérapie, 114, rue Édouard-Vaillant, 94800 Villejuif, France
| | - Anne Ducassou
- Institut universitaire du cancer de Toulouse oncopole, département de radiothérapie, 1, avenue Irène Joliot-Curie, 31059 Toulouse cedex 9, France
| | - Florence Joly
- Université de Caen, centre François-Baclesse, département de médecine, 3, avenue du Général Harris, 14000 Caen, France
| | | |
Collapse
|
11
|
Boyer O, Baudouin V, Bérard É, Biebuyck-Gougé N, Dossier C, Guigonis V, Audard V, Klifa R, Leroy V, Ranchin B, Roussey G, Samaille C, Tellier S, Vrillon I. [Vaccine recommendations for children with idiopathic nephrotic syndrome]. Nephrol Ther 2020; 16:177-183. [PMID: 32278737 DOI: 10.1016/j.nephro.2019.09.007] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2019] [Accepted: 09/17/2019] [Indexed: 11/16/2022]
Abstract
The specific treatment of idiopathic nephrotic syndrome is based on corticosteroid therapy and/or steroid-sparing immunosuppressive agents in children who are steroid-dependant or frequent relapsers (60-70 %). Patients have an increased infectious risk not only related to the disease during relapses (hypogammaglobulinemia and urinary leakage of opsonins) but also to treatments (corticosteroids or immunosuppressive agents) in period of remission. Vaccination is therefore particularly recommended in these patients. Potential vaccine risks are ineffectiveness, induction of vaccine disease and relapse of idiopathic nephrotic syndrome. Only live vaccines expose to the risk of vaccine disease: they are in general contra-indicated under immunosuppressive treatment. The immunogenicity of inactivated vaccines is reduced but persists. The immunogenic stimulus of vaccination may in theory trigger a relapse of the nephrotic syndrome. Nevertheless, this risk is low in the literature, and even absent in some studies. The benefit-risk ratio is therefore in favor of vaccination with respect to the vaccination schedule for inactivated vaccines, with wide vaccination against pneumococcus and influenza annually. Depending on the context and after expert advice, immunization with live vaccines could be discussed if residual doses/levels of immunosuppressive treatments are moderate and immunity preserved.
Collapse
Affiliation(s)
- Olivia Boyer
- Service de néphrologie pédiatrique, centre de référence du syndrome néphrotique idiopathique de l'enfant et de l'adulte, hôpital Necker-Enfants-malades, institut Imagine, université de Paris, 149, rue de Sèvres, 75015 Paris, France.
| | - Véronique Baudouin
- Service de néphrologie pédiatrique, centre de référence du syndrome néphrotique idiopathique de l'enfant et de l'adulte, hôpital Robert-Debré, institut Imagine, université de Paris, 48, boulevard Sérurier, 75935 Paris cedex 19, France
| | - Étienne Bérard
- Service de néphrologie pédiatrique, CHU de Nice, Archet 2, 151, route Saint-Antoine de Ginestière, CS 23079, 06202 Nice cedex 3, France
| | - Nathalie Biebuyck-Gougé
- Service de néphrologie pédiatrique, centre de référence du syndrome néphrotique idiopathique de l'enfant et de l'adulte, hôpital Necker-Enfants-malades, institut Imagine, université de Paris, 149, rue de Sèvres, 75015 Paris, France
| | - Claire Dossier
- Service de néphrologie pédiatrique, centre de référence du syndrome néphrotique idiopathique de l'enfant et de l'adulte, hôpital Robert-Debré, institut Imagine, université de Paris, 48, boulevard Sérurier, 75935 Paris cedex 19, France
| | - Vincent Guigonis
- Département de pédiatrie, hôpital Mère-Enfant, 8, avenue Dominique-Larrey, 87042 Limoges cedex, France
| | - Vincent Audard
- Inserm U955, service de néphrologie et transplantation, centre de référence du syndrome néphrotique idiopathique de l'enfant et de l'adulte, université Paris-Est Créteil, CHU Henri Mondor, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94010 Créteil, France
| | - Roman Klifa
- Service de néphrologie pédiatrique, centre de référence du syndrome néphrotique idiopathique de l'enfant et de l'adulte, hôpital Necker-Enfants-malades, institut Imagine, université de Paris, 149, rue de Sèvres, 75015 Paris, France
| | - Valérie Leroy
- Service de néphrologie pédiatrique, CHU La Réunion, Site Félix Guyon, allée des Topazes, CS 11021, 97400 Saint-Denis, Réunion
| | - Bruno Ranchin
- Service de néphrologie pédiatrique, centre de référence néphrogone, CHU de Lyon, 59, boulevard Pinel, 69500 Bron, France
| | - Gwenaëlle Roussey
- Clinique médicale pédiatrique, CHU de Nantes, 5, allée de l'Île Gloriette, 44093 Nantes, France
| | - Charlotte Samaille
- Service de néphrologie pédiatrique, hôpital Jeanne de Flandre, centre hospitalo-universitaire de Lille, avenue Eugène-Avinée, 59000 Lille, France
| | - Stéphanie Tellier
- Service de néphrologie-rhumatologie-médecine interne pédiatrique, centre de référence des Maladies rénales rares du Sud-Ouest (SORARE), hôpital des enfants, 330, avenue de Grande-Bretagne, 31300 Toulouse, France
| | - Isabelle Vrillon
- Service de médecine infantile, secteur de néphrologie pédiatrique, hôpital d'Enfants de Brabois, CHRU de Nancy, rue du Morvan, 54500 Vandœuvre-lès-Nancy, France
| |
Collapse
|
12
|
Yossi S, Nguyen D, Krhili S, Lizée T, Khodri M. [Prognosis factors after lung stereotactic body radiotherapy for non-small cell lung carcinoma]. Cancer Radiother 2020; 24:267-74. [PMID: 32192839 DOI: 10.1016/j.canrad.2019.11.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2019] [Revised: 10/27/2019] [Accepted: 11/05/2019] [Indexed: 10/24/2022]
Abstract
Lung cancer is the fourth most common cancer in France with a prevalence of 30,000 new cases per year. Lobectomy surgery with dissection is the gold standard treatment for T1-T2 localized non-small cell lung carcinoma. A segmentectomy may be proposed to operable patients but fragile from a respiratory point of view. For inoperable patients or patients with unsatisfactory pulmonary function tests, local treatment with stereotactic radiotherapy may be proposed to achieve local control rates ranging from 85 to 95% at 3-5 years. Several studies have examined prognostic factors after stereotaxic pulmonary radiotherapy. We conducted a general review of the literature to identify factors affecting local control.
Collapse
|
13
|
Vollmer HC, Domma J. [Differences in the success rates of inpatient therapy for alcohol and illegal drug abusers. A Replication Study]. Encephale 2019; 46:102-109. [PMID: 31866104 DOI: 10.1016/j.encep.2019.09.008] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2019] [Revised: 09/15/2019] [Accepted: 09/28/2019] [Indexed: 11/25/2022]
Abstract
INTRODUCTION Irrespective of the type of psychotherapy used, the abstinence-oriented treatment of drug abusers is less successful than that for alcohol abusers. If, on the other hand, the two groups are parallelized in such a way that the patients are identical with respect to the five characteristics of gender, age, schooling, work situation and partner situation, then there is no difference between the success rates of the drug and alcohol abusers. The aim of this study is to determine whether this result can be replicated in another therapeutic institution. METHOD Retrospective field study of 320 abusers of illegal drugs and 320 alcohol abusers who were treated with behaviour therapy. By combining the binary characteristics gender, work situation and age, the drug-dependent patients were divided into 23=8 groups, and the same number of alcohol abusers were randomly selected for each group. The scheduled period of inpatient treatment was 90 days for the alcohol abusers and 120 days for the drug abusers. Every week the patients had one session of individual psychotherapy and four to five group therapy sessions. According to the indications, the certified behaviour therapists implemented the following interventions including behaviour analysis, relapse prevention, cognitive therapy, self-management and behavioural family therapy. Comparison of the success rates was carried out using the Chi2 test, and changes in the psychological findings were tested with one-way variance analysis. RESULTS There was no difference between drug and alcohol abusers with respect to the rate of therapy termination according to plan (around 80%). A total of 48% of the drug abusers and 41 % of the alcohol abusers who could be followed up had been continuously abstinent at the one-year catamnesis without a single relapse. There were also no differences between the two groups when it was assumed that the patients who could not be followed up had relapsed. In the case of both the drug and alcohol abusers the abstinence rate was highest in over-29-year-old employed men (57.6%; 48.4%). The abstinence rate was lowest in employed female drug abusers (27.8%) and young, unemployed female drug abusers (0%, n=11). DISCUSSION What appears to influence the abstinence rate after inpatient treatment is not only the type of substance consumed but also sociodemographic characteristics. In addition to individually tailored therapy, our results confirm the importance of a highly differentiated presentation of the outcomes of therapy in the specialist literature. An average rate of abstinence (e.g. 30%) is insufficient to evaluate an intervention unless information is also provided about the patients for which the intervention is suitable and those for which it is not. In accordance with the Reproducibility Project, we consider replication studies essential in psychotherapy, even though in practice the considerable methodical requirements can only be partially fulfilled.
Collapse
Affiliation(s)
- H C Vollmer
- IFT Institut für Therapieforschung, Leopoldstr. 175, 80804 München, Allemagne.
| | - J Domma
- Salus Klinik, Rodderstr. 7a, 50354 Hürth, Allemagne
| |
Collapse
|
14
|
Yafour N, Couturier MA, Azarnoush S, Girault S, Hermet E, Masouridi Levrat S, Schmidt A, Michallet M, Etancelin P, Guillaume T, Malard F, Sirvent A, Yakoub-Agha I, Poiré X. [Second allogeneic hematopoietic stem cell transplant: Guidelines from the francophone Society of bone marrow transplantation and cellular therapy (SFGM-TC)]. Bull Cancer 2018; 106:S40-S51. [PMID: 30409466 DOI: 10.1016/j.bulcan.2018.05.018] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2018] [Accepted: 05/31/2018] [Indexed: 01/10/2023]
Abstract
Disease recurrence and graft dysfunction after allogeneic hematopoietic stem cell transplantation (allo-HSCT) currently remain among the major causes of treatment failure in malignant and non-malignant hematological diseases. A second allo-HSCT is a valuable therapeutic option to salvage those situations. During the 8th annual harmonization workshops of the french Society of bone marrow transplantation and cellular therapy (SFGM-TC), a designated working group reviewed the literature in order to elaborate unified guidelines on feasibility, indications, donor choice and conditioning in the case of a second allo-HSCT. In case of relapse, a second allo-HSCT with reduced intensity or non-myeloablative conditioning is a reasonable option, particularly in patients with a good performance status (Karnofsky/Lansky>80%), low co-morbidity score (EBMT score≤3), a longer remission duration after the first allo-HSCT (>6 months), and who present low disease burden at the time of second allo-HSCT. Matched related donors tend to be associated with better outcomes. In the presence of graft dysfunction (primary and secondary graft rejection), an immunoablative conditioning regimen is recommended. A donor change remains a valid option, especially in the absence of graft-versus-host disease after the first allo-HSCT.
Collapse
Affiliation(s)
- Nabil Yafour
- Établissement Hospitalier et Universitaire 1er-Novembre 1954, service d'hématologie et de thérapie cellulaire, BP 4166, 31000 Ibn Rochd, Oran, Algérie; Université d'Oran 1, Ahmed Ben Bella, faculté de médecine, Oran, Algérie.
| | - Marie Anne Couturier
- Hôpital Morvan, institut cancérologie-hématologie, CHRU Brest, 2, avenue Foch, 29200 Brest, France
| | - Saba Azarnoush
- Université Paris Diderot, hôpital Robert-Debré, service d'immuno-hématologie pédiatrique, 48, boulevard Sérurier, 75019 Paris, France
| | - Stéphane Girault
- CHU Limoges, hématologie clinique et thérapie cellulaire, 2, avenue Martin-Luther-King, 87042 Limoges, France
| | - Eric Hermet
- Université d'Auvergne EA3846, CIC-501, CHU Estaing, service de thérapie cellulaire et d'hématologie clinique adulte, Clermont-Ferrand, 58, rue Montalembert, 63000 Clermont-Ferrand, France
| | - Stavroula Masouridi Levrat
- Geneva university hospitals, division of hematology, department of medical specialties, rue Gabrielle-Perret-Gentil 4, 1205 Geneva, Suisse
| | - Aline Schmidt
- CHU d'Angers, maladies du sang, 4, rue Larrey, 49100 Angers, France; Université d'Angers, Inserm U892/CNRS 6299, 49035 Angers, France
| | - Mauricette Michallet
- Centre hospitalier Lyon Sud, hématologie clinique, 165, chemin du Grand-Revoyet, 69495 Pierre-Bénite cedex Lyon, France
| | - Pascaline Etancelin
- Centre Henri-Becquerel, laboratoire de génétique oncologique, rue d'Amiens, 76000 Rouen, France
| | - Thierry Guillaume
- CHU de Nantes, Hôtel-Dieu, service d'hématologie, 1, place Ricordeau, 44000 Nantes, France
| | - Florent Malard
- AP-HP, hôpital Saint-Antoine, service d'hématologie et de thérapie cellulaire, 75012 Paris, France
| | - Anne Sirvent
- CHU Montpellier, hôpital Arnaud-de-Villeneuve, service de l'onco-hématologie pédiatrique, 371, avenue du Doyen-Gaston-Giraud, 34090 Montpellier, France
| | - Ibrahim Yakoub-Agha
- CHU de Lille, maladies du sang, unité d'Allogreffe de CSH, 59000 Lille, France; Université de Lille 2, LIRIC, Inserm U995, 59000 Lille, France
| | - Xavier Poiré
- Cliniques universitaires Saint-Luc, service d'hématologie, 10, avenue Hippocrate, 1200 Bruxelles, Belgique
| |
Collapse
|
15
|
Mjid M, Hedhli A, Zakhma M, Zribi M, Ouahchi Y, Toujani S, Cherif J. [Clinical and microbiological profile of patients experiencing relapses of tuberculosis in Tunisia]. Rev Pneumol Clin 2018; 74:76-80. [PMID: 29402488 DOI: 10.1016/j.pneumo.2018.01.002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/18/2017] [Revised: 01/07/2018] [Accepted: 01/08/2018] [Indexed: 06/07/2023]
Abstract
INTRODUCTION Relapse of tuberculosis (TB) is known to be as one of the major risk factors for resistant TB. The aim of this study is to focus on clinical, radiological and bacteriological features of patients with pulmonary TB relapse. METHODS We performed a retrospective survey in the respiratory department of the teaching hospital La Rabta in Tunis between January 2000 and December 2014. Data of patients with a pulmonary TB relapse were analyzed. RESULTS During the study period, among 1250 patients hospitalized for pulmonary TB, 44 had a TB relapse. The TB relapse rate was estimated to be at 3.5%. The average age was 43.95±16.7 years. Sex ratio was 5,2. Eighty one percent of patients were current smokers. Alcoholism was found in 40.9% of cases. The mean time to relapse was 6.37±3.7 years. The radiological lesions were moderately extended at least in 54.6% of cases. A resistant TB was found in 33% of cases (mono-resistance: 33.3%, multi-drug resistance (TB-MR): 11,1%, poly-resistance: 55.5%). The most incriminated drugs were isoniazid, rifampicin and pyrazinamide. One patient received TB-MR treatment regimen for 18 months. In the other cases, the duration of treatment was prolonged. Recovery was obtained in 72.7% of cases, two patients died and 22.7% of patients were lost to follow up. CONCLUSION In Tunisia, TB relapse usually affects young male patients who are often alcoholic and smokers. Resistant TB is frequent among these patients. These findings lead us to emphasize the need of rapid diagnosis tools and adapted treatment regimen in these patients.
Collapse
Affiliation(s)
- M Mjid
- Service de pneumo-allergologie, unité de recherche 12SP06, faculté de médecine de Tunis, université de Tunis El Manar, CHU La Rabta, 1007 Tunis
| | - A Hedhli
- Service de pneumo-allergologie, unité de recherche 12SP06, faculté de médecine de Tunis, université de Tunis El Manar, CHU La Rabta, 1007 Tunis.
| | - M Zakhma
- Service de pneumo-allergologie, unité de recherche 12SP06, faculté de médecine de Tunis, université de Tunis El Manar, CHU La Rabta, 1007 Tunis
| | - M Zribi
- Service de bactériologie, faculté de médecine de Tunis, université de Tunis El Manar, CHU La Rabta, 1007 Tunis
| | - Y Ouahchi
- Service de pneumo-allergologie, unité de recherche 12SP06, faculté de médecine de Tunis, université de Tunis El Manar, CHU La Rabta, 1007 Tunis
| | - S Toujani
- Service de pneumo-allergologie, unité de recherche 12SP06, faculté de médecine de Tunis, université de Tunis El Manar, CHU La Rabta, 1007 Tunis
| | - J Cherif
- Service de pneumo-allergologie, unité de recherche 12SP06, faculté de médecine de Tunis, université de Tunis El Manar, CHU La Rabta, 1007 Tunis
| |
Collapse
|
16
|
Kurtz JE, D'Hondt V, Lécuru F, Lhommé C. Prise en charge du cancer du col de l’utérus métastatique et/ou en rechute. Bull Cancer 2017; 104 Suppl 1:S39-42. [PMID: 28625314 DOI: 10.1016/S0007-4551(17)30161-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
METASTATIC OR RECURRENT CERVICAL CANCER/TREATMENT The prognosis of metastatic or recurrent cervical cancer remains dismal. The poor chemosensitivity of this tumor- is an issue, especially in case of recurrence in irradiated fields. Still, chemotherapy has shown some efficacy, and mostly consists in platinum-based doublets. The addition of bevacizumab to chemotherapy has been recently validated. However, most of these patients present with complex clinical situations and the treatment strategy has to be discussed in multidisciplinary tumor boards.
Collapse
|
17
|
Gladieff L, Lyonnet DS, Lortholary A, Leary A, Genestie C, Ray-Coquard I. Cancers de l’ovaire BRCA muté : consultation d’oncogénétique et prescription des inhibiteurs de PARP. Bull Cancer 2017. [PMID: 28625311 DOI: 10.1016/s0007-4551(17)30158-3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Abstract
BRCA MUTATED OVARIAN CARCINOMAS GENETIC COUNSELING AND PARP INHIBITORS PRESCRIPTION: Upon the availability of the PARP inhibitors in relapsed ovarian carcinoma, the pathways of the oncogenetic counseling were modified. Any research for a constitutional alteration of the BRCA1 and BRCA2 genes must be accompanied by an oncogenetic counseling. BRCA testing is recommended from the diagnosis to every woman with an ovarian or fallopian tube or peritoneum of high grade adenocarcinoma, whatever the age at the diagnosis and her family history. In case of sensitive relapse or potential inclusion in a clinical trial and in the absence of preliminary constitutional research, the oncogenetic counseling is organized according to a fast track pathway and a somatic analysis can be realized in parallel. Today, olaparib is indicated for patients with a high grade serous ovarian or fallopian tube or peritoneum adenocarcinoma, with deleterious mutation of BRCA genes (constitutional or somatic), and in sensitive platinum relapse, and in maintenance therapy after a response to chemotherapy including platinum. The indication of a treatment with olaparib can be discussed in multidisciplinary staff for the other non-serous high grade ovarian carcinoma if all other criteria are gathered. Olaparib is prescribed in monotherapy, to start at the latest 8 weeks after the last chemotherapy cycle, under narrow surveillance, because of its gastrointestinal and hematologic toxicities.
Collapse
Affiliation(s)
- Laurence Gladieff
- Département d'oncologie médicale, institut Claudius-Regaud, 1, avenue Irène-Joliot-Curie, IUCT-Oncopole, 31059 Toulouse, Cedex 9, France.
| | | | - Alain Lortholary
- Le Confluent centre Catherine-de-Sienne, 2, rue Éric-Tabarly, 44202 Nantes, Cedex 2, France
| | - Alexandra Leary
- Département d'oncologie médicale, Gustave -Roussy, 114, rue Édouard-Vaillant, 94800 Villejuif, France
| | - Catherine Genestie
- Département de pathologie, Gustave-Roussy, 114, rue Édouard-Vaillant, 94800 Villejuif, France
| | - Isabelle Ray-Coquard
- Département d'oncologie médicale, centre Léon-Bérard, 28, rue Laennec, 69008 Lyon et university Claude-Bernard, Lyon I, France
| |
Collapse
|
18
|
Colin O, Julian A, Puyade M, Bouyer S, Meurin E, Blondeau S, Houeto JL, Neau JP. [Relapse of acute promyelocytic leukemia in the central nervous system revealed by isolated dementia]. Rev Med Interne 2016; 37:844-848. [PMID: 27020402 DOI: 10.1016/j.revmed.2016.02.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2015] [Revised: 12/16/2015] [Accepted: 02/26/2016] [Indexed: 11/18/2022]
Abstract
INTRODUCTION Approximately 1.5% of dementia is due to curable aetiology. We report an isolated dementia syndrome due to a meningeal relapse of acute promyelocytic leukaemia with favourable outcome after appropriate treatment. CASE REPORT A 72-year-old woman, in remission of an acute promyelocytic leukaemia, presented a loss of autonomy for several months due to corticosubcortical dementia. Lumbar puncture showed blast cells indicating meningeal relapse of leukaemia. Intrathecal chemotherapy and arsenic trioxide obtained biological and molecular remission as well as restoration of normal cognitive functions. CONCLUSION In patients with hematologic past history such as acute promyelocytic leukaemia, an isolated cognitive impairment should alert physicians to search for an isolated neuromeningeal relapse.
Collapse
Affiliation(s)
- O Colin
- Service de neurologie et neuropsychologie, CHU de Poitiers, 2, rue de la Milétrie, 86021 Poitiers, France.
| | - A Julian
- Service de neurologie et neuropsychologie, CHU de Poitiers, 2, rue de la Milétrie, 86021 Poitiers, France; Centre mémoire de ressources et de recherche Poitou-Charentes, CHU de Poitiers, 2, rue de la Milétrie, 86021 Poitiers, France
| | - M Puyade
- Service d'onco-hématologie, CHU de Poitiers, 2, rue de la Milétrie, 86021 Poitiers, France
| | - S Bouyer
- Laboratoire d'hématologie, CHU de Poitiers, 2, rue de la Milétrie, 86021 Poitiers, France
| | - E Meurin
- Centre mémoire de ressources et de recherche Poitou-Charentes, CHU de Poitiers, 2, rue de la Milétrie, 86021 Poitiers, France
| | - S Blondeau
- Centre mémoire de ressources et de recherche Poitou-Charentes, CHU de Poitiers, 2, rue de la Milétrie, 86021 Poitiers, France
| | - J L Houeto
- Service de neurologie et neuropsychologie, CHU de Poitiers, 2, rue de la Milétrie, 86021 Poitiers, France; Centre mémoire de ressources et de recherche Poitou-Charentes, CHU de Poitiers, 2, rue de la Milétrie, 86021 Poitiers, France
| | - J P Neau
- Service de neurologie et neuropsychologie, CHU de Poitiers, 2, rue de la Milétrie, 86021 Poitiers, France; Centre mémoire de ressources et de recherche Poitou-Charentes, CHU de Poitiers, 2, rue de la Milétrie, 86021 Poitiers, France
| |
Collapse
|
19
|
Kouamé-N'Takpé N, Horo K, Koné A, N'guessan KR, Touré K, Kouadio C, Assi D, Coulibaly I, Kouakou A. [Clinical, microbiological and evolutionary profile of patients experiencing failures and relapses of tuberculosis in Ivory Coast]. Rev Pneumol Clin 2015; 71:20-26. [PMID: 25681315 DOI: 10.1016/j.pneumo.2014.11.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/11/2014] [Revised: 10/09/2014] [Accepted: 11/01/2014] [Indexed: 06/04/2023]
Abstract
INTRODUCTION Multidrug-resistant tuberculosis (MDR-TB) is a major obsession for TB control. The main risk factor for MDR-TB remains a history of TB treatment especially bad conduct. The objective of this study is to describe the profile of patients in situations of failure and relapse of tuberculosis. METHODS We performed a retrospective survey of the analysis of records of patients starting TB retreatment for failure or relapse of tuberculosis. We used 193 cases with results of culture-sensitivity. RESULTS The proportion of failure is 59/193 (30.6 %) and cases of relapse are 134/193 (69.4 %). The proportion of married life is 23.4 % (11/47) in chess against 41.5 % (51/123) in relapse of TB [P=0.021, OR=0.431 (0.201 to 0.927)]. Patients failing therapy have more chest pain [5.8 % (3/52) versus 0 % (0/126) with P=0.024]. The proportion of MDR-TB was 61.4 (38/59) in case of failure against 41 % (55/134) in case of relapse [P=0.002, OR=2.599 (1.378 to 4.902)]. The evolution is the same whatever the indication of reprocessing. CONCLUSION The proportion of MDR-TB is very important in case of reprocessing failure and relapse of tuberculosis.
Collapse
Affiliation(s)
| | - K Horo
- Service de pneumologie, CHU de Cocody, Abidjan, Côte d'Ivoire
| | - A Koné
- Service de pneumologie, CHU de Cocody, Abidjan, Côte d'Ivoire
| | - K R N'guessan
- Unité de mycobactérie, Institut Pasteur, Abidjan, Côte d'Ivoire
| | - K Touré
- Centre antituberculeux, Adjamé, Côte d'Ivoire
| | - C Kouadio
- Service de pneumologie, CHU de Cocody, Abidjan, Côte d'Ivoire
| | - D Assi
- Centre antituberculeux, Adjamé, Côte d'Ivoire
| | - I Coulibaly
- Centre antituberculeux, Yopougon, Côte d'Ivoire
| | - A Kouakou
- Programme national de lutte contre la tuberculose, Abidjan, Côte d'Ivoire
| |
Collapse
|
20
|
Yossi S, El Alouani C, Pointreau Y, Laccourreye L, Capitain O, Gustin P, Peyraga G, Septans AL, Jadaud É, Vinchon-Petit S, Cellier P, Autret D, Tuchais C. [Recurrence sites following definitive intensity-modulated conformational radiotherapy of squamous-cell carcinomas of the upper aerodigestive tract]. Cancer Radiother 2015; 19:73-81. [PMID: 25623256 DOI: 10.1016/j.canrad.2014.10.006] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2014] [Revised: 10/10/2014] [Accepted: 10/15/2014] [Indexed: 11/28/2022]
Abstract
PURPOSE The implementation of intensity-modulated radiotherapy (IMRT) in a centre requires regular critical review of medical practices and feedback to optimize the subsequent management of patients. PATIENTS AND METHODS We reviewed and determined through a retrospective single-centre study recurrence sites of 167 consecutive patients treated for head and neck squamous cell carcinoma excluding skin or sinuses. Patients had mostly stage III or IV locally advanced cancer (n=123). RESULTS Locoregional control rates at 1 and 2 years were respectively 87.9% (95% confidence interval [95%CI]: 81.6%-92.1%) and 77.6% (95%CI: 70.1%-83.5). Among 55 relapses, 20 patients (36.4%) had treatment failures. Patients treated with 70 Gy relapsed mainly in high risk volume (78%). Those treated with 66 Gy recurred regionally outside the irradiated volume (n=4) or in the irradiated high risk volume (n=3) or had isolated metastatic failure (n=3). Those irradiated with 50 Gy had regional relapse outside the irradiated volume (n=2) or isolated metastatic relapse (n=2). We noticed respectively 5.4%, 10.2% and 4.2% isolated metastatic, local, cervical lymph node relapse. CONCLUSION Our results are consistent with data from the literature. Corrective actions were performed to enhance our practices.
Collapse
Affiliation(s)
- S Yossi
- Département de radiothérapie, institut de cancérologie de l'Ouest Paul-Papin, 2, rue Moll, 49933 Angers cedex 9, France.
| | - C El Alouani
- Département de radiothérapie, institut de cancérologie de l'Ouest Paul-Papin, 2, rue Moll, 49933 Angers cedex 9, France; Département de radiothérapie, centre hospitalier universitaire de Marrakech, Marrakech, Maroc
| | - Y Pointreau
- Centre Jean-Bernard-clinique Victor-Hugo, 9, rue Beauverger, 72000 Le Mans, France
| | - L Laccourreye
- Service d'ORL et de chirurgie maxillofaciale, centre hospitalier universitaire d'Angers, 4, rue Larrey, 49100 Angers, France
| | - O Capitain
- Département d'oncologie médicale, institut de cancérologie de l'Ouest Paul-Papin, 2, rue Moll, 49933 Angers cedex 9, France
| | - P Gustin
- Département de radiothérapie, institut de cancérologie de l'Ouest Paul-Papin, 2, rue Moll, 49933 Angers cedex 9, France
| | - G Peyraga
- Département de radiothérapie, institut de cancérologie de l'Ouest Paul-Papin, 2, rue Moll, 49933 Angers cedex 9, France
| | - A-L Septans
- Délégation à la recherche clinique et à l'innovation, institut de cancérologie de l'Ouest Paul-Papin, 2, rue Moll, 49933 Angers cedex 9, France
| | - É Jadaud
- Département de radiothérapie, institut de cancérologie de l'Ouest Paul-Papin, 2, rue Moll, 49933 Angers cedex 9, France
| | - S Vinchon-Petit
- Département de radiothérapie, institut de cancérologie de l'Ouest Paul-Papin, 2, rue Moll, 49933 Angers cedex 9, France
| | - P Cellier
- Département de radiothérapie, institut de cancérologie de l'Ouest Paul-Papin, 2, rue Moll, 49933 Angers cedex 9, France
| | - D Autret
- Département de physique médicale, institut de cancérologie de l'Ouest Paul-Papin, 2, rue Moll, 49933 Angers cedex 9, France
| | - C Tuchais
- Département de radiothérapie, institut de cancérologie de l'Ouest Paul-Papin, 2, rue Moll, 49933 Angers cedex 9, France
| |
Collapse
|